Health AI Central
Peer-Reviewed Publication
J Clin Oncol2025;43(23):2639-2654.August 10, 2025Journal Article

Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma.

Chris Labaki1,2,3, Eddy Saad1,3, Katrine N Madsen3, Charbel Hobeika4,5, Kevin Bi1, Michel Alchoueiry5, Sabrina Camp1, Yue Hou6, Ziad Bakouny7, Sayed Matar8, Nourhan El Ahmar8, Jackson Nyman9, Long Zhang10, Carmen Priolo5, Rishabh Rout3, Melissa Daou11, Damir Khabibullin5, Samer Salem5, Nicholas Schindler3, Renée Maria Saliby3,11, Kevin Meli12, J Connor Wells13, Erica Pimenta1, Kosuke Takemura14, Jihye Park1, Marc Eid1, Karl Semaan1, Jingxin Fu1, Thomas Denize15, Razane El Hajj Chehade1, Marc Machaalani1, Rashad Nawfal1, Wassim Daoud Khatoun1, Mustafa Saleh1, Jad El Masri1, Nina Rossa Haddad16, Wenxin Xu1, Bradley A McGregor1, Michelle S Hirsch8, Wanling Xie1, Daniel Y C Heng14, David F McDermott17, Sabina Signoretti8, Eliezer M Van Allen1, Sachet A Shukla18, Toni K Choueiri1, Elizabeth P Henske5, David A Braun3
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
2Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
3Center of Molecular and Cellular Oncology (CMCO), Yale School of Medicine, New Haven, CT.
4Department of Medicine, Cleveland Clinic Fairview Hospital, Cleveland, OH.
5Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
6Akoya Biosciences Inc, Marlborough, MA.
7Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
8Department of Pathology, Brigham and Women's Hospital, Boston, MA.
9PathAI, Inc, Boston, MA.
10University of Shanghai for Science and Technology, Shanghai, China.
11Department of Medicine, Yale University, New Haven, CT.
12RBC Capital Markets, New York, NY.
13BC Cancer Agency, Vancouver, Canada.
14Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.
15Department of Pathology, Massachusetts General Hospital, Boston, MA.
16Johns Hopkins University School of Medicine, Baltimore, MD.
17Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
18Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Texas, Houston, TX.
PubMed PMC DOI PDF

Abstract

PURPOSE: While immune checkpoint inhibition (ICI) has transformed the management of many advanced renal cell carcinomas (RCCs), the determinants of effective antitumor immunity for chromophobe RCC (ChRCC) and renal oncocytic tumors remain an unmet clinical and scientific need. METHODS: Single-cell transcriptomic and T-cell receptor profiling was performed on tumor and adjacent normal tissue of pa…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.